Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Mar. 22, 2019 | Jun. 30, 2018 | |
Document and Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2018 | ||
Document Fiscal Year Focus | 2018 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | DarioHealth Corp. | ||
Entity Central Index Key | 0001533998 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Public Float | $ 20,786,954 | ||
Trading Symbol | DRIO | ||
Entity Common Stock, Shares Outstanding | 36,821,173 | ||
Entity Shell Company | false | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 10,997 | $ 3,718 |
Short-term restricted bank deposits | 180 | 258 |
Trade receivables | 168 | 282 |
Inventories | 1,377 | 1,184 |
Other accounts receivable and prepaid expenses | 591 | 604 |
Total current assets | 13,313 | 6,046 |
LEASE DEPOSITS | 43 | 42 |
PROPERTY AND EQUIPMENT, NET | 733 | 869 |
Total assets | 14,089 | 6,957 |
CURRENT LIABILITIES: | ||
Trade payables | 2,574 | 1,852 |
Deferred Revenues | 736 | 0 |
Other accounts payable and accrued expenses | 1,854 | 1,163 |
Total current liabilities | 5,164 | 3,015 |
LIABILITY RELATED TO WARRANTS | 0 | 1 |
STOCKHOLDERS' EQUITY | ||
Common Stock of $0.0001 par value -Authorized: 160,000,000 shares at December 31, 2018 and 2017; Issued and Outstanding: 36,607,755 and 14,074,238 shares at December 31, 2018 and 2017, respectively | 8 | 7 |
Preferred Stock of $0.0001 par value - Authorized: 5,000,000 shares at December 31, 2018 and 2017; Issued and Outstanding: None at December 31, 2018 and 2017 | 0 | 0 |
Additional paid-in capital | 98,171 | 74,892 |
Accumulated deficit | (89,254) | (70,958) |
Total stockholders' equity | 8,925 | 3,941 |
Total liabilities and stockholders' equity | $ 14,089 | $ 6,957 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Dec. 31, 2018 | Dec. 31, 2017 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 160,000,000 | 160,000,000 |
Common stock, shares issued | 36,607,755 | 14,074,238 |
Common stock, shares, outstanding | 36,607,755 | 14,074,238 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Revenues | $ 7,394 | $ 5,170 |
Cost of revenues | 5,629 | 3,859 |
Gross profit | 1,765 | 1,311 |
Operating expenses: | ||
Research and development | 3,676 | 3,297 |
Sales and marketing | 10,309 | 7,707 |
General and administrative | 5,468 | 4,726 |
Total operating expenses | 19,453 | 15,730 |
Operating loss | 17,688 | 14,419 |
Financial expenses, net: | ||
Expenses (income) from revaluation of warrants | (1) | 1,168 |
Other financial expense, net | 116 | 156 |
Total financial expenses, net | 115 | 1,324 |
Net loss | 17,803 | 15,743 |
Deemed dividend | 493 | 255 |
Net loss attributable to holders of Common Stock | $ 18,296 | $ 15,998 |
Net loss per share: | ||
Basic and diluted loss per share | $ 0.78 | $ 1.64 |
Weighted average number of Common Stock used in computing basic and diluted net loss per share | 23,412,891 | 9,628,256 |
STATEMENTS OF CHANGES IN STOCKH
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($) $ in Thousands | Total | Common Stock [Member] | Preferred Stock [Member] | Additional Paid-in Capital [Member] | Accumulated deficit [Member] | ||||
Balance at Dec. 31, 2016 | $ (6,541) | $ 6 | $ 0 | $ 48,413 | $ (54,960) | ||||
Balance (in shares) at Dec. 31, 2016 | 5,713,383 | 0 | |||||||
Issuance of Common Stock in January 2017 Private Placement, net of issuance cost | 2,936 | $ 0 | [1] | $ 0 | 2,936 | 0 | |||
Issuance of Common Stock in January 2017 Private Placement, net of issuance cost (In Shares) | 1,113,922 | 0 | |||||||
Payment for executives and directors under Stock for Salary Program | 707 | $ 0 | [1] | $ 0 | 707 | 0 | |||
Payment for executives and directors under Stock for Salary Program (in shares) | 271,880 | 0 | |||||||
Issuance of Common Stock to Employees | 1,514 | $ 0 | [1] | $ 0 | 1,514 | 0 | |||
Issuance of Common Stock to Employees (In Shares) | 474,880 | 0 | |||||||
Issuance of Common Stock to consultants and service provider | 874 | $ 0 | [1] | $ 0 | 874 | 0 | |||
Issuance of Common Stock to consultants and service provider (in shares) | 281,681 | 0 | |||||||
Issuance of Common Stock in March 2017 Private Placement, net of issuance cost | 1,878 | $ 0 | [1] | $ 0 | 1,878 | 0 | |||
Issuance of Common Stock in March 2017 Private Placement, net of issuance cost (In Shares) | 707,515 | 0 | |||||||
Reclassification of warrants from liability to equity on March 8, 2017 | 8,655 | $ 0 | $ 0 | 8,655 | 0 | ||||
Issuance of Common Stock in April 2017 Public offering, net of issuance cost | 3,855 | $ 1 | $ 0 | 3,854 | 0 | ||||
Issuance of Common Stock in April 2017 Public offering, net of issuance cost (In Shares) | 1,450,000 | 0 | |||||||
Exercise of options | 0 | [1] | $ 0 | [1] | $ 0 | 0 | [1] | 0 | |
Exercise of options (In Shares) | 91,855 | 0 | |||||||
Issuance of Common stock in November 2017 warrant exchange agreement | 0 | [1] | $ 0 | [1] | $ 0 | 0 | 0 | ||
Issuance of Common stock in November 2017 warrant exchange agreement (in shares) | 1,039,676 | 0 | |||||||
Issuance of Common Stock in 2018 Private Placements, net of issuance cost | 801 | $ 0 | [1] | $ 0 | 801 | 0 | |||
Issuance of Common Stock in 2018 Private Placements, net of issuance cost (In Shares) | 483,333 | 0 | |||||||
Issuance of Preferred Stock in 2018 Private placement, net of issuance cost | 3,711 | $ 0 | $ 0 | [1] | 3,711 | 0 | |||
Issuance of Preferred Stock in 2018 Private placement, net of issuance cost (In Shares) | 0 | 2,307,654 | |||||||
Conversion of Preferred Stock to Common Stock | 0 | $ 0 | [1] | $ 0 | [1] | 0 | 0 | ||
Conversion of Preferred Stock to Common Stock (In Shares) | 2,307,654 | (2,307,654) | |||||||
Deemed dividend related to Stock dividend | 0 | $ 0 | [1] | $ 0 | 255 | (255) | |||
Deemed dividend related to Stock dividend (In Shares) | 138,459 | 0 | |||||||
Stock-based compensation | 1,294 | $ 0 | $ 0 | 1,294 | 0 | ||||
Net loss | (15,743) | 0 | 0 | 0 | (15,743) | ||||
Balance at Dec. 31, 2017 | 3,941 | $ 7 | $ 0 | 74,892 | (70,958) | ||||
Balance (in shares) at Dec. 31, 2017 | 14,074,238 | 0 | |||||||
Payment for executives and directors under Stock for Salary Program | $ 1,055 | $ 0 | [1] | $ 0 | 1,055 | 0 | |||
Payment for executives and directors under Stock for Salary Program (in shares) | 369,993 | 765,695 | 0 | ||||||
Issuance of Common Stock to Directors and Employees | $ 1,786 | $ 0 | [1] | $ 0 | 1,786 | 0 | |||
Issuance of Common Stock to Directors and Employees (In Shares) | 1,152,840 | 0 | |||||||
Issuance of Common Stock to consultants and service provider | $ 504 | $ 0 | [1] | $ 0 | 504 | 0 | |||
Issuance of Common Stock to consultants and service provider (in shares) | 369,993 | 0 | |||||||
Exercise of options (In Shares) | 0 | ||||||||
Issuance of Common stock in May 2018 warrant exchange agreement | $ 0 | $ 0 | [1] | $ 0 | 493 | (493) | |||
Issuance of Common stock in May 2018 warrant exchange agreement (In Shares) | 636,752 | 0 | |||||||
Issuance of Common Stock in 2018 Private Placements, net of issuance cost | 9,354 | $ 1 | $ 0 | 9,353 | 0 | ||||
Issuance of Common Stock in 2018 Private Placements, net of issuance cost (In Shares) | 9,579,069 | 0 | |||||||
Issuance of Preferred Stock in 2018 Private placement, net of issuance cost | 9,269 | $ 0 | $ 0 | [1] | 9,269 | 0 | |||
Issuance of Preferred Stock in 2018 Private placement, net of issuance cost (In Shares) | 0 | 3,124,337 | |||||||
Conversion of Preferred Stock to Common Stock | 0 | $ 0 | [1] | $ 0 | [1] | 0 | 0 | ||
Conversion of Preferred Stock to Common Stock (In Shares) | 10,029,188 | (3,124,337) | |||||||
Stock-based compensation | 819 | $ 0 | $ 0 | 819 | 0 | ||||
Net loss | (17,803) | 0 | 0 | 0 | (17,803) | ||||
Balance at Dec. 31, 2018 | $ 8,925 | $ 8 | $ 0 | $ 98,171 | $ (89,254) | ||||
Balance (in shares) at Dec. 31, 2018 | 36,607,775 | 0 | |||||||
[1] | Represents an amount lower than $1. |
CONSOLIDATED STATEMENT OF CASH
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | ||
Cash flows from operating activities: | |||
Net loss | $ (17,803) | $ (15,743) | |
Adjustments required to reconcile net loss to net cash used in operating activities: | |||
Stock-based compensation and Common Stock to service providers | 3,758 | 3,824 | |
Depreciation | 207 | 195 | |
Decrease (increase) in trade receivables | 114 | (56) | |
Decrease (increase) in other accounts receivable and prepaid expenses | 13 | (99) | |
Increase in inventories | (193) | (295) | |
Increase in trade payables | 722 | 39 | |
Increase in deferred revenues | 736 | 0 | |
Increase in other accounts payable and accrued expenses | 977 | 334 | |
Change in the fair value of warrants to purchase shares of Common Stock | (1) | 1,168 | |
Revaluation of short-term restricted bank deposits | 0 | (17) | |
Loss from disposal of fixed assets | 0 | 31 | |
Net cash used in operating activities | (11,470) | (10,619) | |
Cash flows from investing activities: | |||
Maturity (investment) in short-term restricted bank deposits | 78 | (17) | |
Investment in lease deposit | (1) | (7) | |
Purchase of property and equipment | (71) | (195) | |
Net cash provided by (used in) investing activities | 6 | (219) | |
Cash flows from financing activities: | |||
Proceeds from exercise of warrants | 0 | 0 | [1] |
Proceeds from issuance of shares and warrants, net of issuance cost | 18,743 | 13,463 | |
Net cash provided by financing activities | 18,743 | 13,463 | |
Increase in cash and cash equivalents | 7,279 | 2,625 | |
Cash and cash equivalents at beginning of year | 3,718 | 1,093 | |
Cash and cash equivalents at end of year | 10,997 | 3,718 | |
Non-cash investing and financing activities: | |||
Reclassification of warrants from liability to equity | 0 | 8,655 | |
Payment for executives and directors under Salary Program | $ 201 | $ 183 | |
[1] | Represents an amount lower than $1. |
GENERAL
GENERAL | 12 Months Ended |
Dec. 31, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | NOTE 1:- GENERAL a. DarioHealth Corp. (the “Company”) was incorporated in Delaware and commenced operations on August 11, 2011. In July 2016, the Company’s Board of Directors approved the change of the Company’s name to DarioHealth Corp., which became effective on July 28, 2016. The Company is a digital health (mHealth) company that is developing and commercializing a patented and proprietary technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s flagship product, Dario™, also referred to as the Dario™ Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on an innovative, multi-feature software application combined with a stylish, ‘all-in-one’, pocket-sized, blood glucose monitoring device, which is called the Dario™ Smart Meter. b. The Company’s wholly owned subsidiary, LabStyle Innovation Ltd. (“Ltd.” or “Subsidiary”), was incorporated and commenced operations on September 14, 2011 in Israel. Its principal business activity is to hold the Company’s intellectual property and to perform research and development, manufacturing, marketing and other business activities. Ltd. has a wholly-owned subsidiary, LabStyle Innovations US LLC, a Delaware limited liability company (“LabStyle US”), which was established in 2014, however it has not started its operations to date and was dissolved by the end of 2017. c. During the year ended December 31, 2018, the Company incurred recurring operating losses and negative cash flows from operating activities amounting to $17,803 and $11,470, respectively. The Company will be required to obtain additional liquidity resources in the near term in order to support the commercialization of its products and maintain its research and development activities. The Company is addressing its liquidity needs by seeking additional funding from public and/or private sources and by ramping up its commercial sales. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the short and long-term development and commercialization of its product. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. d. In December 2015, the United States Food and Drug Administration (“FDA”) granted the Subsidiary 510(k) clearance for the Dario Blood Glucose Monitoring System, including its components, the Dario Blood Glucose Meter, Dario Blood Glucose Test Strips, Dario Glucose Control Solutions and the Dario app on the Apple iOS 6.1 platform and higher. e. On March 4, 2016, the Company’s Common Stock and warrants were approved for listing on the Nasdaq Capital Market under the symbols “DRIO” and “DRIOW,” respectively. |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”). a. Use of estimates: The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP and the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material. Management believes the Company’s critical accounting policies and estimates are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. b. Financial statements in U.S. dollars (“$”, “dollar” or “dollars”): The accompanying consolidated financial statements have been prepared in dollars. The Company’s financing activities are incurred in U.S. dollars. Although a portion of the Subsidiary’s expenses is denominated in New Israeli Shekels (“NIS”) (mainly cost of personnel), a substantial portion of its expenses is denominated in dollars. Accordingly, the Company’s management believes that the currency of the primary economic environment in which the Company and its subsidiary operate is the dollar; thus, the dollar is the functional currency of the Company. Transactions and balances denominated in dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with Accounting Standard Codification (“ASC”) 830, “Foreign Currency Matters”. All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated. d. Cash and cash equivalents: The Company considers all highly liquid investments, which are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash equivalents. e. Short-term restricted bank deposits: Short-term bank deposits are restricted deposits with maturities of up to one year and are pledged in favor of the bank as a security for the Company’s rent and credit payments. The short-term bank deposits are denominated in NIS and bear interest at an average rate of 0.02% and 0.01% as of December 31, 2018 and 2017, respectively. The short-term bank deposits are presented at their cost, including accrued interest. f. Inventories: Inventories are stated at the lower of cost plus allocable indirect costs or net realized value. Cost is determined on a “moving average” basis. Inventory write-down is provided to cover technological obsolescence, excess inventories and discontinued products. Inventory write-down represents the difference between the cost of the inventory and net realizable value. Inventory write-down is charged to the cost of revenues and ramp up of manufacturing when a new lower cost basis is established. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials. Total write-offs during the years ended December 31, 2018 and 2017 amounted to $41 and $190, respectively. g. Long-term lease deposits: Long-term lease deposits include mainly long-term deposits for the Company’s leased vehicles. h. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computers, and peripheral equipment 15-33 Office furniture and equipment 6 Production lines 33 Leasehold improvements Over the shorter of the lease term or useful economic life i. Impairment of long-lived assets: Property and equipment are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Through December 31, 2018, no impairment was noted. j. Revenue recognition: Revenues from product sales are recognized in accordance with ASC 605-10 “Revenue Recognition”, when delivery has occurred, persuasive evidence of an agreement exists, the vendor’s fee is fixed or determinable, no further obligation exists and collectability is probable. The Company derives revenues from the sale of its devices and its related device-specific disposables test strip cartridges and lancets through independent distributors or directly to end users. The Dario software application is offered for a free download and the Company does not obtain a recurring hosting commitment towards the end users relating specifically to the application. The Company generally has a standard contract with its distributors. According to the agreements, all sales to distributors are final, no rights of return or price protection right is granted to such distributors and the Company is not a party of the agreements between distributors and their customers. When a sales arrangement contains multiple elements, such as services and products, the Company allocates revenue to each element based on a selling price hierarchy as required according to ASC 605-25, “Multiple-Element Arrangements”. The selling price for a deliverable is based on its Vendor Specific Objective Evidence (“VSOE”), if available, third party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE nor TPE is available. The best estimate of selling price is established considering several internal factors including, but not limited to, historical sales, pricing practices and geographies in which the Company offers its products. Revenues from services are recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred or the services have been rendered, the fee is fixed or determinable and collectability is probable. k. Cost of revenues: Cost of revenues is comprised of the cost of production, shipping and handling inventory, personnel and related overhead costs, depreciation of production line and related equipment costs and inventory write-downs. l. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term bank deposits and trade receivables. All of the cash and cash equivalents and short-term bank deposits of the Company and its Subsidiary are invested in deposits and current accounts with major U.S. and Israeli banks. Such cash and cash equivalents and short-term bank deposits may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents and short-term bank deposits may be redeemed and therefore a minimal credit risk exists with respect to these deposits and investments. The Company’s trade receivables are derived mainly from sales to distributers and to end-users world-wide. The Company performs ongoing credit evaluations of its customers. An allowance for doubtful accounts is determined with respect to those specific amounts that the Company has determined to be doubtful of collection. The Company had no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. m. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). This guidance prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are more likely than not to be realized. As of December 31, 2018 and 2017 a full valuation allowance was provided by the Company. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2018 and 2017, no liability for unrecognized tax benefits was recorded as a result of the implementation of ASC 740. n. Research and development costs: Research and development costs are charged to the consolidated statements of comprehensive loss, as incurred. o. Liability Warrants: The Company accounts for certain warrants held by investors and the Company’s previous placement agent and its permitted designees which include certain net settlement cash features as a liability according to the provisions of ASC 815-40, “Derivatives and Hedging - Contracts in Entity’s Own Equity” (“ASC 815”), which provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify to be a derivative financial instrument. The Company measures the warrants at fair value by using Black-Scholes-Merton option-pricing model in each reporting period until they are exercised or expired, with changes in the fair values being recognized in the Company’s statement of comprehensive loss as financial income or expense. p. Accounting for stock-based compensation: The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation - Stock Compensation” (“ASC 718”), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statement of comprehensive loss. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon historical volatility of the Company. The expected option term represents the period that the Company’s stock options are expected to be outstanding and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The Company applies ASC 505-50, “Equity-Based Payments to Non-Employees” with respect to options and warrants issued to non-employees. q. Fair value of financial instruments: The Company applies ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the investments are categorized as Level 3. The carrying amounts of cash and cash equivalents, short-term bank deposits, trade receivables, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Warrants were classified within Level 3 because they are valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant. The Company has no financial assets or liabilities measured using Level 1, Level 2, or Level 3 inputs. r. Basic and diluted net loss per share: Basic net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each year, plus dilutive potential Common Stock considered outstanding during the year, in accordance with ASC 260, “Earnin gs Per Shar e”. The total number of shares related to the outstanding warrants and options excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,787,801 and 1,434,924 for the year ended December 31, 2018 and 2017, respectively. s. Severance pay: Since inception date, all of Ltd.’s employees who are entitled to receive severance pay in accordance with the applicable law in Israel are included under section 14 of the Israeli Severance Compensation Law (“Section 14”). Under this section, they are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Payments in accordance with Section 14 release Ltd. from any future severance payments in respect of those employees. Deposits under Section 14 are not recorded as an asset in the Company’s balance sheet t. Legal and other contingencies: From time to time the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. u. Impact of recently issued accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2014-09, “Revenue from Contracts with Customers” Topic 606). This ASU provides a five-step approach to account for revenue arising from contracts with customers. The ASU requires an entity to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This revenue standard will be effective for the Company starting the first quarter of 2019. The new revenue standard permits companies to either apply the requirements retrospectively to all prior periods presented or apply the requirements in the year of adoption through a modified retrospective approach with a cumulative adjustment. The Company will adopt the new standard effective January 1, 2019, using the modified retrospective transition method. The Company expects the adoption of this guidance will not have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842) ("ASC 842"), relating to the recognition In June 2018 , the FASB issued ASU 2018 - 07 , “Compensation—Stock Compensation (Topic 718) : Improvements to Nonemployee Share-Based Payment Accounting.” The updated guidance simplifies the accounting for nonemployee share-based payment transactions. The amendments in the new guidance specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. For public companies that file with the Securities and Exchange Commission, the standard is effective for financial statements issued for fiscal years beginning after December 15, 2018 , and interim periods within those fiscal years. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606 , “Revenue from Contracts with Customers.” The adoption of this guidance is not expected to have a material impact on the Company’s financial statements. In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This guidance will be effective from the first quarter of 2019 and early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements and related disclosures. |
OTHER ACCOUNTS RECEIVABLE AND P
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES | 12 Months Ended |
Dec. 31, 2018 | |
Other Accounts Receivable And Prepaid Expenses Disclosure [Abstract] | |
Other Accounts Receivable And Prepaid Expenses Disclosure [Text Block] | NOTE 3:- OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES December 31, 2018 2017 Prepaid expenses $ 454 $ 451 Deferred costs 71 - Government authorities 66 153 $ 591 $ 604 |
INVENTORIES
INVENTORIES | 12 Months Ended |
Dec. 31, 2018 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | NOTE 4:- INVENTORIES December 31, 2018 2017 Raw materials $ 424 $ 323 Finished products 953 861 $ 1,377 $ 1,184 |
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET | 12 Months Ended |
Dec. 31, 2018 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 5:- PROPERTY AND EQUIPMENT, NET Composition of assets, grouped by major classification, is as follows: December 31, 2018 2017 Cost: Computers and peripheral equipment $ 180 $ 285 Office furniture and equipment 114 106 Production lines 736 814 Leasehold improvement 143 141 1,173 1,346 Accumulated depreciation: Computers and peripheral equipment 97 208 Office furniture and equipment 25 20 Production lines 301 246 Leasehold improvement 17 3 440 477 Property and equipment, net $ 733 $ 869 Depreciation expenses for the year ended December 31, 2018 and 2017 amounted to $207 and $195, respectively. |
OTHER ACCOUNTS PAYABLE AND ACCR
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES | 12 Months Ended |
Dec. 31, 2018 | |
Accounts Payable and Accrued Liabilities [Abstract] | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | NOTE 6:- OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES December 31, 2018 2017 Employees and payroll accruals $ 974 $ 735 Accrued expenses 880 428 $ 1,854 $ 1,163 |
COMMITMENTS AND CONTINGENT LIAB
COMMITMENTS AND CONTINGENT LIABILITIES | 12 Months Ended |
Dec. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 7:- COMMITMENTS AND CONTINGENT LIABILITIES a. The facilities and motor vehicles of the Company and its Subsidiary are leased under several operating lease agreements. Ltd. is party to a lease agreement in Israel for a period of 5 years starting from November 2017, for additional 60 months. In addition, Ltd. is a party to a lease agreement expiring on November 2019. Commencing November 13, 2011 and through the year ended 2021, Ltd. also entered into several motor vehicle lease agreements for a period of 36 months. As of December 31, 2018, the Company maintains 11 leased cars. b. As of December 31, 2018, the future minimum aggregate lease commitments under non-cancelable operating lease agreements are as follows: As of ended December 31, Facilities Motor vehicles Total 2019 215 87 302 2020 215 43 258 2021 215 13 228 2022 197 - 197 $ 842 $ 143 $ 985 Facility and motor vehicle lease expenses for the year ended December 31, 2018 and 2017 were $351 and $301, respectively. c. As of December 31, 2018, Ltd. established guarantees to cover rent agreements and credit cards commitments that amounted to $118. |
TAXES ON INCOME
TAXES ON INCOME | 12 Months Ended |
Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | NOTE 8:- TAXES ON INCOME The Company and Ltd. are separately taxed under the domestic tax laws of the state of incorporation of each entity a. Tax Reform On December 22, 2017, the U.S. Tax Cuts and Jobs Act of 2017 (the “TCJA”) was signed into law. The TCJA makes broad and complex changes to the Internal Revenue Code of 1986 (the “Code”) that impact the Company's provision for income taxes. The changes include, but are not limited to: · Decreasing the corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017 (“Rate Reduction”); · The Deemed Repatriation Transition Tax; and · Taxation of Global Intangible Low-Taxed Income (“GILTI”) earned by foreign subsidiaries beginning after December 31, 2017. The GILTI tax imposes a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. Accounting for the TCJA In March 2018, the FASB issued ASU 2018-05, "Income Taxes Topic (740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118" ("ASU 2018-05"), to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared or analyzed (including computations), in reasonable detail, to complete the accounting for certain income tax effects of the TCJA. The Company completed the accounting treatment related to the tax effects of the TCJA. As a result: · The Company recognizes its accounting for changes in the U.S. federal rate and deferred tax impact for the rate change to be complete. · The Company's analysis for the Deemed Repatriation Transition Tax has been filed with its December 31, 2017 tax return and the Company considered its accounting relating to the TCJA to be complete as of such date and did not make any measurement-period adjustments related to it. · The Company accounted for the tax impact related to other areas of the TCJA and believes its analysis to be completed and consistent with the guidance in ASU 2018-05. In particular, the Company concluded that for 2018, it should not be subject to any tax on account of GILTI or base erosion and anti-abuse payments made by U.S. corporations to foreign related parties. The Company recognizes that the Internal Revenue Service, the FASB and the Securities and Exchange Commission are continuing to publish and finalize ongoing guidance with respect to the TCJA which may modify accounting interpretation for the TCJA, the Company will account for these impacts in the period in which any changes are enacted. b. Tax rates applicable to Ltd.: Corporate tax rate in Israel in 2017 was 24% and 2018 was 23%. In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018. c. Net operating loss carryforward: Ltd. has accumulated net operating losses for Israeli income tax purposes as of December 31, 2018 in the amount of approximately $47,233. The net operating losses may be carried forward and offset against taxable income in the future for an indefinite period. As of December 31, 2018, the Company had a U.S. federal net operating loss carryforward of approximately $7,120 that can be carried forward and offset against taxable income and that expires during the years 2031 to 2037. Utilization of U.S. loss carryforward may be subject to substantial annual limitation due to the “change in ownership” provisions of the Code and similar state provisions. The annual limitations may result in the expiration of losses before utilization. The TCJA also modified the rules regarding utilization of net operating losses (“NOL”) and NOLs generated subsequent to the TCJA can only be used to offset 80% of taxable income with an indefinite carryforward period for unused carryforwards (i.e., they should not expire). During 2018, the Company generated an additional $1,965 of NOLs which are not subject to the annual limitation described above. Utilization of the federal and state net operating losses and credits may be subject to a substantial annual limitation due to an additional ownership change. The annual limitation may result in the expiration of net operating losses and credits before utilization and in the event we have a change of ownership, utilization of the carryforwards could be restricted. d. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. December 31, 2018 2017 Deferred tax assets: Net operating loss carry forward $ 10,294 $ 10,794 Temporary differences 791 620 Deferred tax assets before valuation allowance 11,085 11,414 Valuation allowance (11,085 ) (11,414 ) Net deferred tax asset $ - $ - The deferred tax balances included in the consolidated financial statements as of December 31, 2018 are calculated according to the tax rates that were in effect as of the reporting date and do take into account the potential effects of the reduction in the tax rate. The net change in the total valuation allowance for the year ended was a decrease of $ and is mainly relates to increase in deferred taxes on net operating loss for which a full valuation allowance was recorded. In assessing the of deferred tax assets, management considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences and tax loss are deductible. Management considers the projected taxable income and tax-planning strategies in making this assessment. In consideration of the Company’s accumulated losses and the uncertainty of its ability to utilize its deferred tax assets in the future, management currently believes that it is more likely than not that the Company will not realize its deferred tax assets and accordingly recorded a valuation allowance to fully offset all the deferred tax assets. e. Loss before taxes on income consists of the following: Year ended December 31, 2018 2017 Domestic $ 3,801 $ 5,144 Foreign 14,002 10,599 $ 17,803 $ 15,743 f. The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes. |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 12 Months Ended |
Dec. 31, 2018 | |
Equity [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 9:- STOCKHOLDERS’ EQUITY a. The holders of Common Stock have the right to one vote for each share of Common Stock held of record by such holder with respect to all matters on which holders of Common Stock are entitled to vote, to receive dividends as they may be declared in the discretion of the Company’s Board of Directors and to participate in the balance of the Company’s assets remaining after liquidation, dissolution or winding up, ratably in proportion to the number of shares of Common Stock held by them after giving effect to any rights of holders of preferred stock. Except for contractual rights of certain investors, the holders of Common Stock have no pre-emptive or similar rights and are not subject to redemption rights and carry no subscription or conversion rights. b. On April 3, 2015, the Company’s Board of Directors approved stock for salary program pursuant to which the Company will issue compensation shares of restricted Common Stock (“Compensation Shares”) to directors, officers and employees of the Company as consideration for a reduction in or waiver of cash salary, bonus or fees owed to such individuals. The waiver of cash salary will be done upon the average closing price of the Common Stock for the 30 trading days prior to the date the Compensation Shares are granted. During the year ended and , the Company issued and , respectively, Compensation Shares to certain members of the Board of Directors, officers and employees as consideration for a waiver of cash owed to such individuals amounting to $ and $ , respectively. c. On March 8, 2016, the Company closed a public offering (the “Public Offering”) of 1,333,333 shares of the Common Stock, at a purchase price of $4.50 per share, and 1,333,333 immediately exercisable five-year warrants (the “March 2016 Warrants”) each to purchase one share of Common Stock with an exercise price of $4.50 per share, at a purchase price of $0.01 per Warrant for a consideration of $5,038, net of issuance costs. Out of the above issuance, 111,112 shares of Common Stock were issued to the Chief Financial Officer of the Company for gross proceeds of $500. The March 2016 Warrants are exercisable for cash or on a cashless basis if no registration statement covering the resale of the shares issuable upon exercise of the Warrants is available. The March 2016 Warrant included an exercise price adjustment feature for a twelve months period from the issuance date that will adjust the warrant exercise price in case the Company will issue securities in a price lower than $4.50 per share and therefore accounted as a liability according to the provision of ASC 815-40 “Contracts in entity’s own equity”. Following the January 2017 private placement, the exercise price of the warrant was adjusted to $4.34 per share. On March 3, 2016, concurrent with the Public Offering, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain existing shareholders (the “Investors”) with respect to the sale in a private placement (the “Private Offering”) of 555,555 of the Company’s units (the “Units”). The purchase price per Unit was $4.50 and the total consideration amounted to $2,500, net of issuance costs. Each Unit sold in the Private Offering is comprised of (i) one share of Common Stock, and (ii) one warrant to purchase 1.2 shares of Common Stock (the “2016 Series A Warrant”) which is immediately exercisable at an exercise price of $4.50 per share of Common Stock and expires 5 years from the date of issuance. In total, in the Private Offering, the Company issued 555,555 shares of Common Stock and 2016 Series A Warrants exercisable for an aggregate of 666,666 shares of Common Stock. The 2016 Series A Warrants are exercisable for cash or on a cashless basis if no registration statement covering the resale of the shares issuable upon exercise of the 2016 Series A Warrants is available. The 2016 Series A Warrant included an exercise price adjustment feature for a twelve months period from the issuance date that will adjust the warrant exercise price in case the Company will issue securities in a price lower than $4.50 per share and therefore accounted as a liability according to the provision of ASC 815-40 “Contracts in entity’s own equity”. Following the January 2017 private placement, the exercise price of the warrant was adjusted to $4.34 per share. On March 8, 2017, the March 2016 Warrant and 2016 Series A Warrant exercise price adjustment feature expired. The Company re-measured the warrant liability on March 8, 2017 and recorded financial expense from revaluation of the warrant in an amount of $1,066 and an amount of $7,644 was classified from liability to equity. d. On August 10, 2016, the Company entered into an agreement (the “Agreement”) with Dicilyon Consulting and Investment Ltd., an existing stockholder (the “Stockholder”), and David Edery, who previously purchased certain securities from the Company, which were granted certain registration right which required, among other things, the continued effectiveness of certain registration statements. In consideration of the Stockholder waiving its registration right with respect to the previously purchased securities, the Company agreed to issue to the Stockholder a warrant, or the Warrant, to purchase 300,000 shares of Common Stock at an exercise price of $4.50 per share exercisable for a period of 4.5 years from the date of the Agreement. In addition, the Company also agreed to register the shares of Common Stock underlying the Warrant. The Warrant is exercisable for cash or on a cashless basis if a registration statement covering the shares issuable upon exercise of the Warrants is unavailable. The Warrant included an exercise price adjustment feature for a seven months period from the issuance date that will adjust the warrant exercise price in case the Company will issue securities in a price lower than $4.50 per share and therefore accounted as a liability according to the provision of ASC 815-40 “Contracts in entity’s own equity”. As a result of the Agreement the Company recorded registration right waiver in the amount of $702 as financial expense, net in 2016. Following the January 2017 private placement, the exercise price of the warrant was adjusted to $4.34 per share. On March 8, 2017, the Warrant exercise price adjustment feature expired. The Company re-measured the warrant liability on March 8, 2017 and recorded financial expense from revaluation of the warrant in an amount of $141 and an amount of $1,011 was classified from liability to equity. e. On January 9, 2017, the Company commenced a private placement offering of up to $5,100 consisting of up to 1,821,437 shares of the Company’s Common Stock and warrants to purchase up to 1,821,437 shares of Common Stock. The warrants are exercisable after the six-month anniversary of each respective closing and will expire on the 5-year anniversary of their issuance. On January 9, 2017, the Company held the initial closing of the offering with a lead investor and an additional investor and issued 1,113,922 shares of Common Stock and warrants to purchase 1,113,922 shares of Common Stock for aggregate gross proceeds of approximately $3,119 ($2,936 net of issuance expenses). On January 11, 2017, the Company entered into securities purchase agreements with certain investors for the future issuance and sale of 707,515 shares of Common Stock and warrants to purchase 707,515 shares of Common Stock, provided that the issuance and sale of such securities shall only occur upon obtaining stockholder approval, pursuant to Nasdaq rules. The Company’s stockholders approved the issuance and sale of the securities on March 9, 2017 and the closing of the private placement offering, with aggregate gross proceeds of $1,981 ($1,878 net of issuance expenses), occurred on March 9, 2017. f. During 2017, the Company’s Compensation Committee of the Board of Directors approved the grants of 756,561 shares of Common Stock to officers, employees, service providers and consultants of the Company. 110,987 of these shares were issued to service provider in lieu of $298 owed in cash to them. The shares were issued under the 2012 Plan. g. On April 5, 2017, the Company closed a public offering (the “2017 Public Offering”) of 1,450,000 shares of Common Stock, at a purchase price of $3.10 per share, for an aggregate consideration of $3,855, net of issuance costs. The shares were offered, issued and sold pursuant to a shelf registration statement filed with the Securities and Exchange Commission. In connection with the 2017 Public Offering, the Company agreed to issue to the representative of the underwriters’ five-year warrants to purchase up to 36,250 shares of Common Stock at an exercise price equal to $3.875 per share of Common Stock for cash or on a cashless basis if no registration statement covering the resale of the shares issuable upon exercise of the warrants is available. h. On August 22, 2017, the Company closed two concurrent private placements offerings consisting of 483,333 shares of the Company’s Common Stock, and 2,307,654 shares of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), for aggregate gross proceeds of approximately $5,024 ($4,793 net of issuance expenses). The shares of Series B Preferred Stock were convertible into an aggregate of 2,307,654 shares of Common Stock based on a conversion price of $1.80 per share. Such conversion price was not subject to any future price-based anti-dilution adjustments except for standard anti-dilution protection. The shares of Series B Preferred Stock were not redeemable nor contingently redeemable. The holders of the Series B Preferred Stock were not entitled to convert such preferred stock into shares of the Company’s Common Stock until the Company obtained stockholder approval for such issuance and upon obtaining such stockholder approval automatically converted into shares of Common Stock. In addition, the holders of the Series B Preferred Stock were entitled to a 6% fixed dividend, payable in shares of Common Stock, to be payable upon the automatic conversion of the Series B Preferred Stock. The holders of the Series B Preferred Stock did not possess any voting rights but the Series B Preferred Stock did carry a liquidation preference for each holder equal to the investment made by such holder in the Offering. In addition, the holders of Series B Preferred Stock were eligible to participate in dividends and other distributions by the Company on an as converted basis. Following approval in December 2017, all the Series B Preferred Stock were converted into 2,307,654 shares of Common Stock and a 6% fixed dividend of 138,459 shares of Common Stock. The Company accounted for the 6% fixed dividend as a deemed dividend in a total amount of $255. i. In November 2017, the Company entered into an exchange agreement (the “Exchange Agreement”) with certain Company warrant holders who were granted warrants to purchase shares of Common Stock on August 10, 2016 and January 2017 private placement. Pursuant to the terms of the Exchange Agreement, the warrant holders agreed to surrender and cancellation of their warrants to purchase an aggregate of 1,871,436 shares of Common Stock and received, as consideration for such cancellation, an aggregate of 1,039,676 shares of Common Stock, creating no benefit to the warrant holders. j. During 2018, the Company’s Compensation Committee of the Board of Directors approved the grants of an aggregate of 369,993 shares of Common Stock in lieu of $504 owed to service providers and the grant of an option to purchase 201,818 shares of Common Stock in lieu of $298 owed to a service provider of the Company. 84,499 shares and the options were issued under the 2012 Plan. k. On February 28, 2018 and March 6, 2018, the Company closed two concurrent private placements offerings consisting of 2,262,269 shares of the Company’s Common Stock at $1.40 per share, 1,234,080 shares of the Company’s Series C Convertible Preferred Stock (the “Series C Preferred Stock”), for aggregate gross proceeds of approximately $6,623 ($6,034 net of issuance expenses) at $2.80 per share, and warrants to purchase up to 3,784,351 shares of Common Stock. The shares of Series C Preferred Stock were convertible into an aggregate of 2,468,160 shares of Common Stock based on a conversion price of $1.40 per share. Such conversion price was not subject to any future price-based anti-dilution adjustments except for standard anti-dilution protection. The shares of Series C Preferred Stock were not redeemable nor contingently redeemable. The holders of the Series C Preferred Stock were not be entitled to convert such preferred stock into shares of the Company’s Common Stock until the Company stockholder approval for such issuance and upon obtaining such stockholder approval, automatically into shares of Common Stock. The holders of the Series C Preferred Stock did not possess any voting rights, but the Series C Preferred Stock did carry a liquidation preference for each holder equal to the investment made by such holder in the Offering. In addition, the holders of Series C Preferred Stock were eligible to participate in dividends and other distributions by the Company on an as converted basis. The warrants issued in the concurrent private placements are exercisable after the six-month anniversary of each respective closing and will expire on the 18-month anniversary of their issuance. Following in May 2018, the shares of Series C Preferred Stock were converted into shares of Common Stock. In conjunction with these offerings the Company issued 32,250 shares of Common Stock to certain finders. The shares were issued under the 2012 Plan. l. In May 2018, the Company entered into exchange agreements (each an “Exchange Agreement”) with certain Company warrant holders who were granted warrants to purchase shares of Common Stock in March 2016 and January 2017. Pursuant to the terms of the Exchange Agreements, the warrant holders agreed to surrender their warrants to purchase an aggregate of 1,020,357 shares of Common Stock for cancellation and received, as consideration for such cancellation, an aggregate of 636,752 restricted shares of Common Stock creating a benefit to the warrant holders. As such the Company recorded a deemed dividend in the amount of $493. m. In June and July 2018, the Company’s Compensation Committee of the Board of Directors approved the grant of an aggregate of 1,152,840 shares to directors, officers, employees and consultants of the Company, and the grant of 244,000 and 21,000 options to employees and consultants of the Company, respectively, at an exercise price of $1.729 per share. The stock options vest over a period of three years commencing on the respective grant dates. All of the aforementioned options have a six-year terms. All shares and options were issued under the 2012 Plan. n. On September 13, 2018 and September 26, 2018, the Company closed private placements offerings consisting of 4,266,800 shares of the Company’s Common Stock at $0.90 per share, 1,890,257 shares of the Company’s Series D Convertible Preferred Stock (the “Series D Preferred Stock”) at $3.60 per share, and warrants to purchase up to 9,462,272 shares of Common Stock, for aggregate gross proceeds of approximately $10,645 ($9,686 net of issuance expenses). The shares of Series D Preferred Stock were convertible into an aggregate of 7,561,028 shares of Common Stock based on a conversion price of $0.90 per share. Such conversion price was not subject to any future price-based anti-dilution adjustments except for standard anti-dilution protection. The shares of Series D Preferred Stock were not redeemable nor contingently redeemable. The holders of the Series D Preferred Stock were not be entitled to convert such preferred stock into shares of the Company’s Common Stock until the Company stockholder approval for such issuance and upon obtaining such stockholder approval, automatically into shares of Common Stock. The holders of the Series D Preferred Stock did not possess any voting rights, but the Series D Preferred Stock did carry a liquidation preference for each holder equal to the investment made by such holder in the Offering. In addition, the holders of Series D Preferred Stock were eligible to participate in dividends and other distributions by the Company on an as converted basis. The warrants issued in the concurrent private placements are exercisable after the six-month anniversary of each respective closing and will expire on the 36-month anniversary of their issuance. Following in November 2018, the shares of Series D Preferred Stock were converted into shares of Common Stock. In conjunction with these offerings the Company issued shares of Common Stock to certain finders. o. On December 13, 2018, and December 27, 2018, the Company closed a private consisting of 3,050,000 shares of the Company’s Common Stock at $1.00 per share and warrants to purchase up to 3,050,000 shares of Common Stock, for aggregate gross proceeds of approximately $3,050 ($3,023 net of issuance expenses). The warrants issued in the private are exercisable after the six-month anniversary of each respective closing and will expire on the 36-month anniversary of their issuance. p. The table below summarizes the outstanding warrants as of December 31, 2018: Warrants outstanding as of December 31, 2018 Exercise price $ Expiration date February 2015 PPM A (*) 4,630 4.32 November 25,2015 March 2016 PPM -Warrants 1,528,333 4.34 March 8, 2021 March 2016 Public Offering - Representative’s Warrants 143,333 5.625 March 8, 2021 March 2017 Public Offering - Representative’s Warrants 36,250 3.875 March 31, 2022 February 2018 PPM 2,811,450 1.80 August 28, 2019 March 2018 PPM 972,901 1.80 September 6, 2019 March 2018 PPM (Finder Warrants) 18,920 1.80 September 6, 2019 September 2018 PPM 9,195,604 1.25 September 13, 2021 September 2018 PPM (Finder Warrants) 140,556 1.25 September 13, 2021 September 2018 PPM 2 nd 266,668 1.25 September 26, 2021 December 2018 PPM 3,000,000 1.25 December 14, 2021 December 2018 PPM – 2 nd 50,000 1.25 December 27, 2021 Total outstanding 18,168,645 (*) Warrants for which cash has been received by the Company but no securities issued. No warrants were exercised in 2018 and 2017. q. Stock-based compensation: On January 23, 2012, an equity incentive plan (the “2012 Plan”) was adopted by the Board of Directors of the Company and approved by a majority of the Company’s stockholders, under which options to purchase shares of Common Stock have been reserved. Under the 2012 Plan, options to purchase shares of Common Stock may be granted to employees and non-employees of the Company or any affiliate, each option granted can be exercised to one share of Common Stock. During 2017, the Company stockholders approved an amendment to the 2012 Plan to increase the number of shares authorized for issuance under the 2012 Plan by 2,000,000 shares, from 1,873,000 to 3,873,000. During 2018, the Company’s stockholders approved an amendment to the 2012 Plan to increase the number of shares authorized for issuance under the 2012 Plan by 5,000,000 shares, from 3,873,000 to 7,873,000. The following options were issued under the 2012 Plan during 2018 and 2017: On January 30, 2017, the Company’s Compensation Committee of the Board of Directors approved the grant of 313,721 options to directors, officers and employees of the Company, at an exercise price of $3.202 per share. The options shall vest over a period of three years commencing on the grant date. All the options have a six-year term. On February 6, 2017, the Company’s Compensation Committee of the Board of Directors approved the grants of 174,000, and 55,050 options to employees and consultants of the Company, respectively, at exercise prices of between $0.0001 and $4.121 per share. The options shall vest over a period of three years commencing on the grant date. All the options have a six-year term. 34,050 of the option to consultants were granted instead of cash owed for services provided during the period from July through December 2016. On June 26, 2017, the Company’s Compensation Committee of the Board of Directors approved the grants of 69,000 and 194,142 options to employees and consultants of the Company, respectively, at exercise prices of between $0.0001 and $2.46 per share. The options shall vest over a period of up to three years commencing on the grant date. 8,142 of the options issued to a consultant were in lieu of a cash waiver of $30 by the consultant. On September 14, 2017, the Company’s Compensation Committee of the Board of Directors approved the grants of 40,000 options a consultant of the Company, at an exercise price of $2.50 per share. The option is fully vested on the grant date, and the option has a five-year term. On December 14, 2017, the Company’s Compensation Committee of the Board of Directors approved the grants of 40,424 options to a consultant of the Company, at an exercise price of $0.0001 per share. The option is fully vested on the grant date and has a six-year term This option was issued in lieu of a cash waiver of $95 by the consultant. On April 23, 2018, the Company’s Compensation Committee of the Board of Directors approved the grants of 93,755 options to a consultant of the Company, at an exercise price of $0.0001 per share. The option is fully vested on the grant date and has a six-year term. This option was issued in lieu of a cash waiver of $150 by the consultant. On July 23, 2018, the Company’s Compensation Committee of the Board of Directors approved the grants of 70,812 options to consultants of the Company, at an exercise price of $0.0001 per share. 62,812 options are fully vested on the grant date, and 8,000 will vest in 12 equal monthly installments. The options have a six-year term. These options were issued in lieu of a cash waiver of $102 by the consultants. In June and July 2018, the Company’s Compensation Committee of the Board of Directors approved the grant of an aggregate of 1,152,840 shares to directors, officers, employees and consultants of the Company, and the grant of 244,000 and 21,000 options to employees and consultants of the Company, respectively, at an exercise price of $1.729 per share. The stock options shall vest over a period of three years commencing on the respective grant dates. All of the aforementioned options have a six-year terms. On November 22, 2018, the Company’s Compensation Committee of the Board of Directors approved the grants of 120,000 options to its President and Chief Commercial Officer, at exercise prices of $0.795 per share. The options will vest over a three years period from the grant date and have a six-year term. On November 22, 2018, the Company’s Compensation Committee of the Board of Directors approved the grants of 37,251 options to consultants of the Company, at an exercise price of $0.0001 per share. The options are fully vested on the grant date and have a six-year term. These options were issued in lieu of a cash waiver of $45 by the consultants. In addition, the Company’s Compensation Committee of the Board of Directors approved the grants of 26,250 options to a consultant of the Company at an exercise price of $0.998 per share. The options will vest over a three years period from the grant date and have a six-year term. On December 10, 2018, the Company’s Compensation Committee of the Board of Directors approved the grants of an aggregate of 47,000 options to employees of the Company, at an exercise price of $0.927 per share. The stock options will vest over a three years period commencing on the grant date and have a six-year term. Transactions related to the grant of options to employees, directors and non-employees under the above plans during the year ended December 31, 2018 were as follows: Number of options Weighted average exercise price Weighted average remaining contractual life Aggregate Intrinsic value $ Years $ Options outstanding at beginning of year 1,378,160 7.39 4.75 437 Options granted 660,068 0.94 Options exercised - - Options forfeited 60,981 6.08 Options expired 189,446 2.38 Options outstanding at end of year 1,787,801 5.59 4.32 368 Options vested and expected to vest at end of year 1,640,510 5.61 4.32 367 Exercisable at end of year 1,261,914 7.11 3.98 364 Weighted average fair value of options granted during the year ended December 31, 2018 and 2017 is $0.56 and $2.07, respectively. The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price on the last day of fiscal 2018 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2018. This amount is impacted by the changes in the fair market value of the Common Stock. The following table presents the assumptions used to estimate the fair values of the options granted to employees and directors in the period presented: Year ended December 31, 2018 2017 Volatility 83.41%-105.38 % 103.52%-154.75 % Risk-free interest rate 2.69%-2.88 % 1.54%-1.83 % Dividend yield 0 % 0 % Expected life (years) 3.5-4.5 3.5-4.5 The following table presents the assumptions used to estimate the fair values of the options granted to non-employees in the period presented: Year ended December 31, 2018 2017 Volatility 82.61%-107.42 % 100.65%-150.84 % Risk-free interest rate 2.41%-2.96 % 1.78%-2.05 % Dividend yield 0 % 0 % Expected life (years) 2.96-5.94 3.67-6 As of December 31, 2018, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $572, which is expected to be recognized over a weighted average period of approximately 1.14 year. The total compensation cost related to all of the Company’s equity-based awards, recognized during year ended December 31, 2018 and 2017 were comprised as follows: Year ended December 31, 2018 2017 Cost of revenues $ 116 $ 138 Research and development 404 316 Sales and marketing 607 581 General and administrative 2,631 2,789 Total stock-based compensation expenses $ 3,758 $ 3,824 |
LIABILITY RELATED TO WARRANTS
LIABILITY RELATED TO WARRANTS | 12 Months Ended |
Dec. 31, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value Disclosures [Text Block] | NOTE 10:- LIABILITY RELATED TO WARRANTS a. On September 23, 2014, the Company consummated a private placement (the “September 2014 Private Placement”). b. The warrants issued in the September 2014 Private Placement contain a net settlement cash feature and liquidated damages penalties and therefore the Company accounts for such warrants as a liability according to the provisions of ASC 815-40 “Contracts in entity’s own equity,” and re-measures such liability using the Binomial option-pricing model as described below. c. In estimating the investors’ warrants in September 2014 Private Placement fair value, the Company used the following assumptions as of December 31, 2017: risk-free interest rates of 1.65%, volatility of 81.44%, dividend yields of 0% and a contractual life of 0.73 (1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. (2) Expected volatility - was calculated based on actual historical stock price movements of the Company over a term that is equivalent to the expected term of the option. (3) Expected life - the expected life was based on the expiration date of the warrants. (4) Expected dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. The changes in Level 3 liabilities associated with the September 2014 Private Placement warrants is measured at fair value on a recurring basis. The following tabular presentation reflects the components of the liability associated with such warrants as of December 31, 2018: Fair value of liability related to warrants Balance at December 31, 2017 $ 1 Change in fair value of warrants during the period (1 ) Balance at December 31, 2018 $ - In September 2018, September 2014 Private Placement warrants expired with no exercise. |
SELECTED STATEMENTS OF OPERATIO
SELECTED STATEMENTS OF OPERATIONS DATA | 12 Months Ended |
Dec. 31, 2018 | |
Quarterly Financial Information Disclosure [Abstract] | |
Quarterly Financial Information [Text Block] | NOTE 11:- SELECTED STATEMENTS OF OPERATIONS DATA Financial expenses (income), net: Year ended December 31, 2018 2017 Bank charges $ 18 $ 171 Foreign currency adjustments losses (gain) 98 (15 ) Change in the fair value of warrants (1 ) 1,168 Total Financial income, net $ 115 $ 1,324 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2018 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 12:- SUBSEQUENT EVENTS In January 2019, 213,402 Compensation Officers and employees of the Company as consideration for a reduction in or waiver of cash salary or fees amounting to $213 owed to such individuals. The shares were issued under the 2012 Plan. |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Use of Estimates, Policy [Policy Text Block] | a. Use of estimates: The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP and the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material. Management believes the Company’s critical accounting policies and estimates are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Reported Currency In Financial Statements [Policy Text Block] | b. Financial statements in U.S. dollars (“$”, “dollar” or “dollars”): The accompanying consolidated financial statements have been prepared in dollars. The Company’s financing activities are incurred in U.S. dollars. Although a portion of the Subsidiary’s expenses is denominated in New Israeli Shekels (“NIS”) (mainly cost of personnel), a substantial portion of its expenses is denominated in dollars. Accordingly, the Company’s management believes that the currency of the primary economic environment in which the Company and its subsidiary operate is the dollar; thus, the dollar is the functional currency of the Company. Transactions and balances denominated in dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with Accounting Standard Codification (“ASC”) 830, “Foreign Currency Matters”. All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate. |
Consolidation, Policy [Policy Text Block] | c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated. |
Cash and Cash Equivalents, Policy [Policy Text Block] | d. Cash and cash equivalents: The Company considers all highly liquid investments, which are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash equivalents. |
Investment, Policy [Policy Text Block] | e. Short-term restricted bank deposits: Short-term bank deposits are restricted deposits with maturities of up to one year and are pledged in favor of the bank as a security for the Company’s rent and credit payments. The short-term bank deposits are denominated in NIS and bear interest at an average rate of 0.02% and 0.01% as of December 31, 2018 and 2017, respectively. The short-term bank deposits are presented at their cost, including accrued interest. |
Inventory, Policy [Policy Text Block] | f. Inventories: Inventories are stated at the lower of cost plus allocable indirect costs or net realized value. Cost is determined on a “moving average” basis. Inventory write-down is provided to cover technological obsolescence, excess inventories and discontinued products. Inventory write-down represents the difference between the cost of the inventory and net realizable value. Inventory write-down is charged to the cost of revenues and ramp up of manufacturing when a new lower cost basis is established. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials. Total write-offs during the years ended December 31, 2018 and 2017 amounted to $41 and $190, respectively. |
Lessor, Leases [Policy Text Block] | g. Long-term lease deposits: Long-term lease deposits include mainly long-term deposits for the Company’s leased vehicles. |
Property, Plant and Equipment, Policy [Policy Text Block] | h. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computers, and peripheral equipment 15-33 Office furniture and equipment 6 Production lines 33 Leasehold improvements Over the shorter of the lease term or useful economic life |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | i. Impairment of long-lived assets: Property and equipment are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Through December 31, 2018, no impairment was noted. |
Revenue Recognition, Software [Policy Text Block] | j. Revenue recognition: Revenues from product sales are recognized in accordance with ASC 605-10 “Revenue Recognition”, when delivery has occurred, persuasive evidence of an agreement exists, the vendor’s fee is fixed or determinable, no further obligation exists and collectability is probable. The Company derives revenues from the sale of its devices and its related device-specific disposables test strip cartridges and lancets through independent distributors or directly to end users. The Dario software application is offered for a free download and the Company does not obtain a recurring hosting commitment towards the end users relating specifically to the application. The Company generally has a standard contract with its distributors. According to the agreements, all sales to distributors are final, no rights of return or price protection right is granted to such distributors and the Company is not a party of the agreements between distributors and their customers. When a sales arrangement contains multiple elements, such as services and products, the Company allocates revenue to each element based on a selling price hierarchy as required according to ASC 605-25, “Multiple-Element Arrangements”. The selling price for a deliverable is based on its Vendor Specific Objective Evidence (“VSOE”), if available, third party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE nor TPE is available. The best estimate of selling price is established considering several internal factors including, but not limited to, historical sales, pricing practices and geographies in which the Company offers its products. Revenues from services are recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred or the services have been rendered, the fee is fixed or determinable and collectability is probable. |
Cost of Sales, Policy [Policy Text Block] | k. Cost of revenues: Cost of revenues is comprised of the cost of production, shipping and handling inventory, personnel and related overhead costs, depreciation of production line and related equipment costs and inventory write-downs. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | l. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term bank deposits and trade receivables. All of the cash and cash equivalents and short-term bank deposits of the Company and its Subsidiary are invested in deposits and current accounts with major U.S. and Israeli banks. Such cash and cash equivalents and short-term bank deposits may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents and short-term bank deposits may be redeemed and therefore a minimal credit risk exists with respect to these deposits and investments. The Company’s trade receivables are derived mainly from sales to distributers and to end-users world-wide. The Company performs ongoing credit evaluations of its customers. An allowance for doubtful accounts is determined with respect to those specific amounts that the Company has determined to be doubtful of collection. The Company had no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. |
Income Tax, Policy [Policy Text Block] | m. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). This guidance prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are more likely than not to be realized. As of December 31, 2018 and 2017 a full valuation allowance was provided by the Company. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2018 and 2017, no liability for unrecognized tax benefits was recorded as a result of the implementation of ASC 740. |
Research and Development Expense, Policy [Policy Text Block] | n. Research and development costs: Research and development costs are charged to the consolidated statements of comprehensive loss, as incurred. |
Warrants [Policy Text Block] | o. Liability Warrants: The Company accounts for certain warrants held by investors and the Company’s previous placement agent and its permitted designees which include certain net settlement cash features as a liability according to the provisions of ASC 815-40, “Derivatives and Hedging - Contracts in Entity’s Own Equity” (“ASC 815”), which provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify to be a derivative financial instrument. The Company measures the warrants at fair value by using Black-Scholes-Merton option-pricing model in each reporting period until they are exercised or expired, with changes in the fair values being recognized in the Company’s statement of comprehensive loss as financial income or expense. |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | p. Accounting for stock-based compensation: The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation - Stock Compensation” (“ASC 718”), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statement of comprehensive loss. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon historical volatility of the Company. The expected option term represents the period that the Company’s stock options are expected to be outstanding and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The Company applies ASC 505-50, “Equity-Based Payments to Non-Employees” with respect to options and warrants issued to non-employees. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | q. Fair value of financial instruments: The Company applies ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the investments are categorized as Level 3. The carrying amounts of cash and cash equivalents, short-term bank deposits, trade receivables, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Warrants were classified within Level 3 because they are valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant. The Company has no financial assets or liabilities measured using Level 1, Level 2, or Level 3 inputs. |
Earnings Per Share, Policy [Policy Text Block] | r. Basic and diluted net loss per share: Basic net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each year, plus dilutive potential Common Stock considered outstanding during the year, in accordance with ASC 260, “Earnin gs Per Shar e”. The total number of shares related to the outstanding warrants and options excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,787,801 and 1,434,924 for the year ended December 31, 2018 and 2017, respectively. |
Severance Pay [Policy Text Block] | s. Severance pay: Since inception date, all of Ltd.’s employees who are entitled to receive severance pay in accordance with the applicable law in Israel are included under section 14 of the Israeli Severance Compensation Law (“Section 14”). Under this section, they are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Payments in accordance with Section 14 release Ltd. from any future severance payments in respect of those employees. Deposits under Section 14 are not recorded as an asset in the Company’s balance sheet |
Commitments and Contingencies, Policy [Policy Text Block] | t. Legal and other contingencies: From time to time the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. |
New Accounting Pronouncements, Policy [Policy Text Block] | u. Impact of recently issued accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2014-09, “Revenue from Contracts with Customers” Topic 606). This ASU provides a five-step approach to account for revenue arising from contracts with customers. The ASU requires an entity to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This revenue standard will be effective for the Company starting the first quarter of 2019. The new revenue standard permits companies to either apply the requirements retrospectively to all prior periods presented or apply the requirements in the year of adoption through a modified retrospective approach with a cumulative adjustment. The Company will adopt the new standard effective January 1, 2019, using the modified retrospective transition method. The Company expects the adoption of this guidance will not have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842) ("ASC 842"), relating to the recognition In June 2018 , the FASB issued ASU 2018 - 07 , “Compensation—Stock Compensation (Topic 718) : Improvements to Nonemployee Share-Based Payment Accounting.” The updated guidance simplifies the accounting for nonemployee share-based payment transactions. The amendments in the new guidance specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. For public companies that file with the Securities and Exchange Commission, the standard is effective for financial statements issued for fiscal years beginning after December 15, 2018 , and interim periods within those fiscal years. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606 , “Revenue from Contracts with Customers.” The adoption of this guidance is not expected to have a material impact on the Company’s financial statements. In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This guidance will be effective from the first quarter of 2019 and early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements and related disclosures. |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Schedule Of Rate Of Depreciation [Table Text Block] | Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computers, and peripheral equipment 15-33 Office furniture and equipment 6 Production lines 33 Leasehold improvements Over the shorter of the lease term or useful economic life |
OTHER ACCOUNTS RECEIVABLE AND_2
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Other Accounts Receivable And Prepaid Expenses Disclosure [Abstract] | |
Other Accounts Receivable And Prepaid Expenses Disclosure [Table Text Block] | December 31, 2018 2017 Prepaid expenses $ 454 $ 451 Deferred costs 71 - Government authorities 66 153 $ 591 $ 604 |
INVENTORIES (Tables)
INVENTORIES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | December 31, 2018 2017 Raw materials $ 424 $ 323 Finished products 953 861 $ 1,377 $ 1,184 |
PROPERTY AND EQUIPMENT, NET (Ta
PROPERTY AND EQUIPMENT, NET (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment [Table Text Block] | Composition of assets, grouped by major classification, is as follows: December 31, 2018 2017 Cost: Computers and peripheral equipment $ 180 $ 285 Office furniture and equipment 114 106 Production lines 736 814 Leasehold improvement 143 141 1,173 1,346 Accumulated depreciation: Computers and peripheral equipment 97 208 Office furniture and equipment 25 20 Production lines 301 246 Leasehold improvement 17 3 440 477 Property and equipment, net $ 733 $ 869 |
OTHER ACCOUNTS PAYABLE AND AC_2
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Accounts Payable and Accrued Liabilities [Abstract] | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | December 31, 2018 2017 Employees and payroll accruals $ 974 $ 735 Accrued expenses 880 428 $ 1,854 $ 1,163 |
COMMITMENTS AND CONTINGENT LI_2
COMMITMENTS AND CONTINGENT LIABILITIES (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | As of ended December 31, Facilities Motor vehicles Total 2019 215 87 302 2020 215 43 258 2021 215 13 228 2022 197 - 197 $ 842 $ 143 $ 985 |
TAXES ON INCOME (Tables)
TAXES ON INCOME (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | Significant components of the Company’s deferred tax assets are as follows: December 31, 2018 2017 Deferred tax assets: Net operating loss carry forward $ 10,294 $ 10,794 Temporary differences 791 620 Deferred tax assets before valuation allowance 11,085 11,414 Valuation allowance (11,085 ) (11,414 ) Net deferred tax asset $ - $ - |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Year ended December 31, 2018 2017 Domestic $ 3,801 $ 5,144 Foreign 14,002 10,599 $ 17,803 $ 15,743 |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | p. The table below summarizes the outstanding warrants as of December 31, 2018: Warrants outstanding as of December 31, 2018 Exercise price $ Expiration date February 2015 PPM A (*) 4,630 4.32 November 25,2015 March 2016 PPM -Warrants 1,528,333 4.34 March 8, 2021 March 2016 Public Offering - Representative’s Warrants 143,333 5.625 March 8, 2021 March 2017 Public Offering - Representative’s Warrants 36,250 3.875 March 31, 2022 February 2018 PPM 2,811,450 1.80 August 28, 2019 March 2018 PPM 972,901 1.80 September 6, 2019 March 2018 PPM (Finder Warrants) 18,920 1.80 September 6, 2019 September 2018 PPM 9,195,604 1.25 September 13, 2021 September 2018 PPM (Finder Warrants) 140,556 1.25 September 13, 2021 September 2018 PPM 2 nd 266,668 1.25 September 26, 2021 December 2018 PPM 3,000,000 1.25 December 14, 2021 December 2018 PPM – 2 nd 50,000 1.25 December 27, 2021 Total outstanding 18,168,645 (*) Warrants for which cash has been received by the Company but no securities issued. No warrants were exercised in 2018 and 2017. |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Transactions related to the grant of options to employees, directors and non-employees under the above plans during the year ended December 31, 2018 were as follows: Number of options Weighted average exercise price Weighted average remaining contractual life Aggregate Intrinsic value $ Years $ Options outstanding at beginning of year 1,378,160 7.39 4.75 437 Options granted 660,068 0.94 Options exercised - - Options forfeited 60,981 6.08 Options expired 189,446 2.38 Options outstanding at end of year 1,787,801 5.59 4.32 368 Options vested and expected to vest at end of year 1,640,510 5.61 4.32 367 Exercisable at end of year 1,261,914 7.11 3.98 364 |
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] | The total compensation cost related to all of the Company’s equity-based awards, recognized during year ended December 31, 2018 and 2017 were comprised as follows: Year ended December 31, 2018 2017 Cost of revenues $ 116 $ 138 Research and development 404 316 Sales and marketing 607 581 General and administrative 2,631 2,789 Total stock-based compensation expenses $ 3,758 $ 3,824 |
Employee And Director [Member] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The following table presents the assumptions used to estimate the fair values of the options granted to employees and directors in the period presented: Year ended December 31, 2018 2017 Volatility 83.41%-105.38 % 103.52%-154.75 % Risk-free interest rate 2.69%-2.88 % 1.54%-1.83 % Dividend yield 0 % 0 % Expected life (years) 3.5-4.5 3.5-4.5 |
Non Employee [Member] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The following table presents the assumptions used to estimate the fair values of the options granted to non-employees in the period presented: Year ended December 31, 2018 2017 Volatility 82.61%-107.42 % 100.65%-150.84 % Risk-free interest rate 2.41%-2.96 % 1.78%-2.05 % Dividend yield 0 % 0 % Expected life (years) 2.96-5.94 3.67-6 |
LIABILITY RELATED TO WARRANTS (
LIABILITY RELATED TO WARRANTS (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Fair value of liability related to warrants Balance at December 31, 2017 $ 1 Change in fair value of warrants during the period (1 ) Balance at December 31, 2018 $ - |
SELECTED STATEMENTS OF OPERAT_2
SELECTED STATEMENTS OF OPERATIONS DATA (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Quarterly Financial Information Disclosure [Abstract] | |
Schedule of Other Nonoperating Income (Expense) [Table Text Block] | Financial expenses (income), net: Year ended December 31, 2018 2017 Bank charges $ 18 $ 171 Foreign currency adjustments losses (gain) 98 (15 ) Change in the fair value of warrants (1 ) 1,168 Total Financial income, net $ 115 $ 1,324 |
GENERAL (Details Textual)
GENERAL (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Organization And Presentation Of Financial Statements [Line Items] | ||
Operating Income (Loss) | $ 17,688 | $ 14,419 |
Net Cash Provided by (Used in) Operating Activities | $ 11,470 | $ 10,619 |
SIGNIFICANT ACCOUNTING POLICI_4
SIGNIFICANT ACCOUNTING POLICIES (Details) | 12 Months Ended |
Dec. 31, 2018 | |
Computers and Peripheral Equipment [Member] | Minimum [Member] | |
Rate Of Depreciation [Line Items] | |
Rate Of Annual Depreciation | 15.00% |
Computers and Peripheral Equipment [Member] | Maximum [Member] | |
Rate Of Depreciation [Line Items] | |
Rate Of Annual Depreciation | 33.00% |
Office Furniture and Equipment [Member] | |
Rate Of Depreciation [Line Items] | |
Rate Of Annual Depreciation | 6.00% |
Production Lines [Member] | |
Rate Of Depreciation [Line Items] | |
Rate Of Annual Depreciation | 33.00% |
Leasehold Improvements [Member] | |
Rate Of Depreciation [Line Items] | |
Annual Depreciation Description | Over the shorter of the lease term or useful economic life |
SIGNIFICANT ACCOUNTING POLICI_5
SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Jan. 01, 2019 | |
Accounting Policies [Line Items] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,787,801 | 1,434,924 | |
Percentage Of Monthly Deposits Behalf Of Insurance Companies | 8.33% | ||
Inventory Write-down | $ 41 | $ 190 | |
Asset Impairment Charges | 0 | ||
Right Of Use Assets and Lease Liabilities Carrying Amount | $ 0 | ||
Subsequent Event [Member] | |||
Accounting Policies [Line Items] | |||
Operating Lease, Right-of-Use Asset | $ 850 | ||
Operating Lease, Liability | $ 890 | ||
Bank Time Deposits [Member] | |||
Accounting Policies [Line Items] | |||
Debt Instrument, Interest Rate, Stated Percentage | 0.02% | 0.01% |
OTHER ACCOUNTS RECEIVABLE AND_3
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Other Accounts Receivable And Prepaid Expenses [Line Items] | ||
Prepaid expenses | $ 454 | $ 451 |
Deferred costs | 71 | 0 |
Government authorities | 66 | 153 |
Prepaid Expense and Other Assets, Current | $ 591 | $ 604 |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Inventory [Line Items] | ||
Raw materials | $ 424 | $ 323 |
Finished products | 953 | 861 |
Inventory, Net | $ 1,377 | $ 1,184 |
PROPERTY AND EQUIPMENT, NET (De
PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Property, Plant and Equipment [Line Items] | ||
Cost | $ 1,173 | $ 1,346 |
Accumulated depreciation | 440 | 477 |
Property and equipment, net | 733 | 869 |
Computers and Peripheral Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 180 | 285 |
Accumulated depreciation | 97 | 208 |
Office Furniture and Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 114 | 106 |
Accumulated depreciation | 25 | 20 |
Production Lines [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 736 | 814 |
Accumulated depreciation | 301 | 246 |
Leasehold Improvement [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 143 | 141 |
Accumulated depreciation | $ 17 | $ 3 |
PROPERTY AND EQUIPMENT, NET (_2
PROPERTY AND EQUIPMENT, NET (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Property, Plant and Equipment [Line Items] | ||
Depreciation | $ 207 | $ 195 |
OTHER ACCOUNTS PAYABLE AND AC_3
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Other Accounts Payable And Accrued Expenses [Line Items] | ||
Employees and payroll accruals | $ 974 | $ 735 |
Accrued expenses | 880 | 428 |
Other Accounts Payable and Accrued Expenses | $ 1,854 | $ 1,163 |
COMMITMENTS AND CONTINGENT LI_3
COMMITMENTS AND CONTINGENT LIABILITIES (Details) $ in Thousands | Dec. 31, 2018USD ($) |
Operating Leased Assets [Line Items] | |
2019 | $ 302 |
2020 | 258 |
2021 | 228 |
2022 | 197 |
Operating Leases, Future Minimum Payments Due, Total | 985 |
Facilities [Member] | |
Operating Leased Assets [Line Items] | |
2019 | 215 |
2020 | 215 |
2021 | 215 |
2022 | 197 |
Operating Leases, Future Minimum Payments Due, Total | 842 |
Motor Vehicles [Member] | |
Operating Leased Assets [Line Items] | |
2019 | 87 |
2020 | 43 |
2021 | 13 |
2022 | 0 |
Operating Leases, Future Minimum Payments Due, Total | $ 143 |
COMMITMENTS AND CONTINGENT LI_4
COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Operating Leased Assets [Line Items] | ||
Operating Leases, Rent Expense, Net | $ 351 | $ 301 |
Credit Card Receivable [Member] | ||
Operating Leased Assets [Line Items] | ||
Other Commitment | 118 | |
Rental Agreement [Member] | ||
Operating Leased Assets [Line Items] | ||
Other Commitment | $ 118 |
TAXES ON INCOME (Details)
TAXES ON INCOME (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Deferred tax assets: | ||
Net operating loss carry forward | $ 10,294 | $ 10,794 |
Temporary differences | 791 | 620 |
Deferred tax assets before valuation allowance | 11,085 | 11,414 |
Valuation allowance | (11,085) | (11,414) |
Net deferred tax asset | $ 0 | $ 0 |
TAXES ON INCOME (Details 1)
TAXES ON INCOME (Details 1) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Valuation Allowance [Line Items] | ||
Domestic | $ 3,801 | $ 5,144 |
Foreign | 14,002 | 10,599 |
Income Loss from Continuing Operations before Income Taxes | $ 17,803 | $ 15,743 |
TAXES ON INCOME (Details Textua
TAXES ON INCOME (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Valuation Allowance [Line Items] | ||
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | 23.00% | 24.00% |
Operating Loss Carryforwards | $ 47,233 | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 329 | |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 35.00% | |
Percentage of income to be offset by net operating loss carry forwards | 80.00% | |
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration | $ 1,965 | |
Scenario, Plan [Member] | ||
Valuation Allowance [Line Items] | ||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | |
Maximum [Member] | ||
Valuation Allowance [Line Items] | ||
Operating Loss Carry forwards Expiration Period | 2037 | |
Minimum [Member] | ||
Valuation Allowance [Line Items] | ||
Operating Loss Carry forwards Expiration Period | 2031 | |
Domestic Tax Authority [Member] | ||
Valuation Allowance [Line Items] | ||
Operating Loss Carryforwards | $ 7,120 |
STOCKHOLDERS' EQUITY (Details)
STOCKHOLDERS' EQUITY (Details) - $ / shares | 12 Months Ended | |||||||
Dec. 31, 2018 | Sep. 26, 2018 | Dec. 31, 2017 | Apr. 05, 2017 | Jan. 31, 2017 | Aug. 10, 2016 | Mar. 08, 2016 | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 18,168,645 | |||||||
Exercise price | $ 504 | $ 0.90 | $ 4.34 | $ 3.875 | $ 4.34 | $ 4.50 | $ 4.50 | |
February 2015 PPM A [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | [1] | 4,630 | ||||||
Exercise price | [1] | $ 4.32 | ||||||
Expiration date | [1] | Nov. 25, 2015 | ||||||
March 2016 PPM Warrants [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 1,528,333 | |||||||
Exercise price | $ 4.34 | |||||||
Expiration date | Mar. 8, 2021 | |||||||
March 2016 Public Offering Representative Warrants [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 143,333 | |||||||
Exercise price | $ 5.625 | |||||||
Expiration date | Mar. 8, 2021 | |||||||
March 2017 Public Offering Representative Warrants [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 36,250 | |||||||
Exercise price | $ 3.875 | |||||||
Expiration date | Mar. 31, 2022 | |||||||
February 2018 PPM [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 2,811,450 | |||||||
Exercise price | $ 1.80 | |||||||
Expiration date | Aug. 28, 2019 | |||||||
March 2018 PPM [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 972,901 | |||||||
Exercise price | $ 1.80 | |||||||
Expiration date | Sep. 6, 2019 | |||||||
March 2018 PPM Warrant [Member] | Finder [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 18,920 | |||||||
Exercise price | $ 1.80 | |||||||
Expiration date | Sep. 6, 2019 | |||||||
September 2018 PPM [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 9,195,604 | |||||||
Exercise price | $ 1.25 | |||||||
Expiration date | Sep. 13, 2021 | |||||||
September 2018 PPM Warrant [Member] | Finder [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 140,556 | |||||||
Exercise price | $ 1.25 | |||||||
Expiration date | Sep. 13, 2021 | |||||||
December 2018 PPM [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 3,000,000 | |||||||
Exercise price | $ 1.25 | |||||||
Expiration date | Dec. 14, 2021 | |||||||
September 2018 PPM 2nd Closing [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 266,668 | |||||||
Exercise price | $ 1.25 | |||||||
Expiration date | Sep. 26, 2021 | |||||||
December 2018 PPM 2nd closing [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Warrants outstanding as of December | 50,000 | |||||||
Exercise price | $ 1.25 | |||||||
Expiration date | Dec. 27, 2021 | |||||||
[1] | Warrants for which cash has been received by the Company but no securities issued. |
STOCKHOLDERS' EQUITY (Details 1
STOCKHOLDERS' EQUITY (Details 1) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Options outstanding at beginning of year, Number of options | 1,378,160 | |
Options granted, Number of options | 660,068 | |
Options exercised, Number of options | 0 | |
Options forfeited, Number of options | 60,981 | |
Options expired, Number of options | 189,446 | |
Options outstanding at end of year, Number of options | 1,787,801 | 1,378,160 |
Options vested and expected to vest at end of year, Number of options | 1,640,510 | |
Exercisable at end of year, Number of options | 1,261,914 | |
Options outstanding at beginning of year, Weighted average exercise price | $ 7.39 | |
Options granted, Weighted average exercise price | 0.94 | |
Options exercised, Weighted average exercise price | 0 | |
Options forfeited, Weighted average exercise price | 6.08 | |
Options expired, Weighted average exercise price | 2.38 | |
Options outstanding at end of year, Weighted average exercise price | 5.59 | $ 7.39 |
Options vested and expected to vest at end of year, Weighted average exercise price | 5.61 | |
Exercisable at end of year, Weighted average exercise price | $ 7.11 | |
Options outstanding at, Weighted Average remaining contractual life | 4 years 3 months 25 days | 4 years 9 months |
Options vested and expected to vest at end of year, Weighted Average remaining contractual life | 4 years 3 months 25 days | |
Exercisable at end of year, Weighted Average remaining contractual life | 3 years 11 months 23 days | |
Options outstanding at beginning of year, Aggregate Intrinsic value | $ 437 | |
Options outstanding at end of year, Aggregate Intrinsic value | 368 | $ 437 |
Options vested and expected to vest at end of year, Aggregate Intrinsic value | 367 | |
Exercisable at end of year, Aggregate Intrinsic value | $ 364 |
STOCKHOLDERS' EQUITY (Details 2
STOCKHOLDERS' EQUITY (Details 2) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Employee And Director [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility, Minimum | 83.41% | 103.52% |
Volatility, Maximum | 105.38% | 154.75% |
Risk-free interest rate, Minimum | 2.69% | 1.54% |
Risk-free interest rate, Maximum | 2.88% | 1.83% |
Dividend yield | 0.00% | 0.00% |
Non Employee [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility, Minimum | 82.61% | 100.65% |
Volatility, Maximum | 107.42% | 150.84% |
Risk-free interest rate, Minimum | 2.41% | 1.78% |
Risk-free interest rate, Maximum | 2.96% | 2.05% |
Dividend yield | 0.00% | 0.00% |
Maximum [Member] | Employee And Director [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected life (years) | 4 years 6 months | 4 years 6 months |
Maximum [Member] | Non Employee [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected life (years) | 5 years 11 months 8 days | 6 years |
Minimum [Member] | Employee And Director [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected life (years) | 3 years 6 months | 3 years 6 months |
Minimum [Member] | Non Employee [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected life (years) | 2 years 11 months 16 days | 3 years 8 months 1 day |
STOCKHOLDERS' EQUITY (Details 3
STOCKHOLDERS' EQUITY (Details 3) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expenses | $ 3,758 | $ 3,824 |
Cost of revenues [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expenses | 116 | 138 |
Research and development [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expenses | 404 | 316 |
Sales and marketing | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expenses | 607 | 581 |
General and administrative [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Total stock-based compensation expenses | $ 2,631 | $ 2,789 |
STOCKHOLDERS' EQUITY (Details T
STOCKHOLDERS' EQUITY (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Dec. 13, 2018 | Dec. 10, 2018 | Mar. 06, 2018 | Feb. 28, 2018 | Dec. 14, 2017 | Sep. 14, 2017 | Mar. 08, 2017 | Feb. 06, 2017 | Jan. 11, 2017 | Aug. 10, 2016 | Mar. 08, 2016 | Mar. 03, 2016 | Nov. 22, 2018 | Sep. 26, 2018 | Jul. 31, 2018 | Jul. 23, 2018 | Jun. 30, 2018 | May 31, 2018 | Apr. 23, 2018 | Dec. 31, 2017 | Aug. 22, 2017 | Jun. 26, 2017 | Apr. 05, 2017 | Mar. 09, 2017 | Jan. 30, 2017 | Jan. 09, 2017 | Mar. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Nov. 29, 2018 | May 18, 2018 | Nov. 30, 2017 | Jan. 31, 2017 | |
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 3,050,000 | $ 500 | $ 3,855 | $ 0 | |||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 660,068 | ||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.94 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,333,333 | 7,561,028 | 1,450,000 | ||||||||||||||||||||||||||||||||
Stock Issued Price Per Share | $ 3.10 | ||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 0.56 | $ 2.07 | |||||||||||||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 572 | ||||||||||||||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 1 month 20 days | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 300,000 | 1,333,333 | 1,020,357 | 36,250 | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 4.50 | $ 4.50 | $ 0.90 | $ 4.34 | $ 3.875 | $ 504 | $ 4.34 | $ 4.34 | |||||||||||||||||||||||||||
Proceeds from Warrant Exercises | $ 3,050 | $ 5,038 | $ 3,023 | ||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 6,034 | $ 5,100 | |||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 26,250 | 8,000 | 369,993 | ||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Share-based Compensation, Gross | $ 1,055 | 707 | |||||||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | (1) | 1,168 | |||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 3,050,000 | 1,871,436 | |||||||||||||||||||||||||||||||||
Warrant Exercise Period | 4 years 6 months | ||||||||||||||||||||||||||||||||||
Other Nonoperating Income | $ 702 | ||||||||||||||||||||||||||||||||||
Service Fees Payable | $ 298 | 298 | |||||||||||||||||||||||||||||||||
Due to Related Parties | $ 45 | ||||||||||||||||||||||||||||||||||
Class Of Warrant Or Right Aggregate with Shares Consideration | 636,752 | 1,039,676 | |||||||||||||||||||||||||||||||||
Dividends, Common Stock, Stock | $ 255 | $ 0 | |||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ 1 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period Shares New Issues February 2014 | 1,821,437 | ||||||||||||||||||||||||||||||||||
Deemed Dividend Related To Warrant Exchange Agreement | $ 493 | ||||||||||||||||||||||||||||||||||
2012 Plan Amendment [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 5,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||
2012 Plan Amendment [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 3,873,000 | 1,873,000 | |||||||||||||||||||||||||||||||||
2012 Plan Amendment [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 7,873,000 | 3,873,000 | |||||||||||||||||||||||||||||||||
Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 6.00% | ||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 6,623 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,234,080 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,468,160 | ||||||||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 138,459 | ||||||||||||||||||||||||||||||||||
Preferred Stock Convertible Conversion Price | $ 1.80 | ||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 2,307,654 | ||||||||||||||||||||||||||||||||||
Preferred Stock Issued During Period Private Placement Share New Issues August 2017 | 2,307,654 | ||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 6.00% | 6.00% | |||||||||||||||||||||||||||||||||
Two Nonus Finder [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Exercisable Term | 5 years | ||||||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | [1] | $ 0 | |||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 3,784,351 | 83,333 | 636,752 | ||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.40 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 765,695 | 271,880 | |||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Share-based Compensation, Gross | [1] | $ 0 | $ 0 | ||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 10,029,188 | 2,307,654 | |||||||||||||||||||||||||||||||||
Dividends, Common Stock, Stock | [1] | $ 0 | |||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | 1.40 | ||||||||||||||||||||||||||||||||||
Preferred Stock Issued During Period Private Placement Share New Issues August 2017 | 0 | 0 | |||||||||||||||||||||||||||||||||
Warrants To Purchase Common Stock Exercise Price Per Share | $ 2.80 | ||||||||||||||||||||||||||||||||||
Series A Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | $ 1,066 | ||||||||||||||||||||||||||||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | 7,644 | ||||||||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 141 | ||||||||||||||||||||||||||||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | $ 1,011 | ||||||||||||||||||||||||||||||||||
U.S. Members of the Board of Director [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 765,695 | 271,880 | |||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Share-based Compensation, Gross | $ 1,055 | $ 707 | |||||||||||||||||||||||||||||||||
Board Of Director And Officers [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.0001 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 84,499 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 298 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 37,251 | ||||||||||||||||||||||||||||||||||
President And Chief Commercial Officer [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.795 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 120,000 | ||||||||||||||||||||||||||||||||||
Employees [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.927 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 47,000 | 174,000 | 244,000 | 244,000 | 69,000 | ||||||||||||||||||||||||||||||
Consultants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.0001 | $ 2.50 | $ 1.729 | $ 0.0001 | $ 0.0001 | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 40,424 | 40,000 | 55,050 | 21,000 | 70,812 | 21,000 | 93,755 | 194,142 | |||||||||||||||||||||||||||
Due to Related Parties | $ 95 | $ 102 | $ 150 | ||||||||||||||||||||||||||||||||
Employees Directors And Consultants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.998 | $ 3.202 | |||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years | ||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 6 years | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 1,152,840 | 1,152,840 | 313,721 | ||||||||||||||||||||||||||||||||
Employees And Consultants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 8,142 | ||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.0001 | ||||||||||||||||||||||||||||||||||
Employee Consultant [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 34,050 | ||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years | ||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 6 years | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 756,561 | ||||||||||||||||||||||||||||||||||
Due to Related Parties | $ 30 | ||||||||||||||||||||||||||||||||||
Employee Consultant [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.0001 | ||||||||||||||||||||||||||||||||||
Employee Consultant [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 4.121 | ||||||||||||||||||||||||||||||||||
Service Provider [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Share-based Compensation, Gross | $ 110,987 | ||||||||||||||||||||||||||||||||||
Service Provider [Member] | Amended And Restated 2012 Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 32,250 | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,262,269 | 2,262,269 | 4,266,800 | 483,333 | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,821,437 | ||||||||||||||||||||||||||||||||||
Warrants Exercise Price Per Share Adjusted | $ 4.34 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 3,119 | ||||||||||||||||||||||||||||||||||
Exercisable Term | 5 years | ||||||||||||||||||||||||||||||||||
Payments of Stock Issuance Costs | $ 2,936 | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ 0.90 | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | Series B Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 5,024 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,307,654 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 4,793 | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,890,257 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 9,686 | ||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ 3.60 | ||||||||||||||||||||||||||||||||||
Gross Proceeds From Private Placement | $ 10,645 | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | Investor [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,113,922 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,113,922 | ||||||||||||||||||||||||||||||||||
Units Issued During Period | 555,555 | ||||||||||||||||||||||||||||||||||
Issuance Of Units Purchase Price Per Unit | $ 4.50 | ||||||||||||||||||||||||||||||||||
Proceeds From Issue Of Units | $ 2,500 | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | Investor [Member] | March 2016 Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 555,555 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 666,666 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 4.50 | ||||||||||||||||||||||||||||||||||
Exercisable Term | 5 years | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 9,462,272 | ||||||||||||||||||||||||||||||||||
Public Offering [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ 4.50 | ||||||||||||||||||||||||||||||||||
Public Offering [Member] | March 2016 Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ 0.01 | ||||||||||||||||||||||||||||||||||
Public Offering [Member] | Chief Financial Officer [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 111,112 | ||||||||||||||||||||||||||||||||||
Securities Purchase Agreements [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 707,515 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 707,515 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 1,981 | ||||||||||||||||||||||||||||||||||
Payments of Stock Issuance Costs | $ 1,878 | ||||||||||||||||||||||||||||||||||
[1] | Represents an amount lower than $1. |
LIABILITY RELATED TO WARRANTS_2
LIABILITY RELATED TO WARRANTS (Details) - Private Placement [Member] $ in Thousands | 12 Months Ended |
Dec. 31, 2018USD ($) | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Balance at December 31, 2016 | $ 1 |
Change in fair value of warrants during the period | (1) |
Balance at December 31, 2017 | $ 0 |
LIABILITY RELATED TO WARRANTS_3
LIABILITY RELATED TO WARRANTS (Details Textual) - September 2014 Private Placement [Member] | 12 Months Ended |
Dec. 31, 2017 | |
Measurement Input, Risk Free Interest Rate [Member] | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Derivative Liability, Measurement Input | 1.65 |
Measurement Input, Price Volatility [Member] | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Derivative Liability, Measurement Input | 81.44 |
Measurement Input, Expected Dividend Rate [Member] | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Derivative Liability, Measurement Input | 0 |
Measurement Input, Expected Term [Member] | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Contractual life | 8 months 23 days |
Measurement Input, Exercise Price [Member] | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Derivative Liability, Measurement Input | 0.01 |
SELECTED STATEMENTS OF OPERAT_3
SELECTED STATEMENTS OF OPERATIONS DATA (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Selected Statements Of Operations Data [Line Items] | ||
Bank charges | $ 18 | $ 171 |
Foreign currency adjustments losses (gain) | 98 | (15) |
Change in the fair value of warrants | (1) | 1,168 |
Total Financial income, net | $ 115 | $ 1,324 |
SUBSEQUENT EVENTS (Details Text
SUBSEQUENT EVENTS (Details Textual) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Jan. 31, 2019 | Nov. 22, 2018 | Jul. 23, 2018 | Dec. 31, 2018 | |
Subsequent Event [Line Items] | ||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 26,250 | 8,000 | 369,993 | |
Due to Related Parties | $ 45 | |||
Subsequent Event [Member] | Board of Director and Officer [Member] | ||||
Subsequent Event [Line Items] | ||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 213,402 | |||
Due to Related Parties | $ 213 |